Proyectos - Internacionales - Programas de Investigación e Innovación de la UE

These projects have received funding from the European UnionThese projects have received funding from the European Union's Horizon 2020 research
and innovation programme under grant agreement which is refrenced under each Project.
Título:
Functional characterisation of mitochondrial metabolic adaptations to innate sensing in dendritic cell subsets
Acrónimo
MITOMAD
Convocatoria:
H2020-ERC-2016-CoG
Referencia:
GA-725091
Investigador principal
David Sancho Madrid
Fecha inicio:
01/12/2017
Fecha fin:
30/11/2023
Presupuesto concedido:
1.995.000,00 €
Fuente de financiación:
EC-European Research Council
Resumen:
We are investigating how tissue damage and microbial signals lead to mitochondrial reprogramming in dendritic cells (DCs) and macrophages, and how manipulation of mitochondrial metabolism regulates myeloid cell function. This project aims to identify new targets to exploit DCs and macrophages for improved immunotherapy. So far we have: 1. Characterized the metabolic reprogramming after DC stimulation with different stimuli both in mouse and human DCs. 2. We are performing the analysis of how innate sensing connects with mitochondrial adaptations in DCs; 3. We have addressed the effect of drugs targeting mitochondrial biology and now we are analyzing the effect of genetic manipulation of mitochondrial biology on DC function in vitro. 4. We are assessing the functional in vivo effects of targeting mitochondrial biology in DCs in homeostasis and disease.

The project aims 1. the analysis of how sensing of external stimuli by DCs leads to mitochondrial adaptations; 2. The investigation in how mitochondrial metabolism may impact in DC function.

The main results obtained in these aims are:
1. In the current reporting period we have found how macrophage polarization is regulated by Fgr kinase-mediated phosphorylation of mitochondrial CII, which impacts on proinflammatory macrophages in the adipose tissue. Fgr deficiency leads to improved glucose metabolism and leaner mice with reduced liver steatosis (Acín-Pérez et al. Nat Metabolism 2020). In addition, we found that a polybacterial preparation induces metabolic reprogramming and trained immunity, protects against viral infection and enhances vaccine immunogenicity (Brandi et al. 2022. Cell Reports; del Fresno et al. Front. Immunol. 2021).
2. Our novel genetic approaches based on CD11c-selective deletion of key proteins affecting OXPHOS complexes have revealed diverse results depending on the targeted complex. We performed the analysis of CD11c-expressing macrophages. We found that distinct physiological functions direct the metabolic requirements of tissue-resident macrophages. Using the CD11c-Cre driver line, we observed a profound phenotype in some CD11c-expressing macrophage (MF) populations. Using our CD11c∆Tfam mice and Lysozyme M-Cre Tfamf/f (LysM∆Tfam) mice, we found that mitochondrial impairment differentially affects presence and identity of MFs correlating with their expression levels of OXPHOS-related genes. Alveolar macrophages are drastically affected and the oxphos is needed for macrophage lipid handling activity. Macrophages in tissues exposed to lipids in homeostasis are more dependent on oxphos for their metabolism. In addition, proinflammatory macrophages in the adipose tissue are also oxphos-dependent. Due to the lack of this proinflammatory macrophages, LysM∆Tfam mice are leaner and show better glucose metabolism and less liver steatosis than control mice (Wculek et al. submitted).

In relation with the previous mentioned objectives, the progress and expected potential are:
1. We have characterized how innate stimuli lead to distinct metabolic signatures and have described modulatory mechanisms that affect metabolic reprogramming and trained immunity (Saz-Leal et al. Cell Reports. 2018). We found that a polybacterial preparation induces metabolic reprogramming and trained immunity, protects against viral infection and enhances vaccine immunogenicity (Brandi et al. 2022. Cell Reports; del Fresno et al. Front. Immunol. 2021).We are now working on new regulators of trained immunity with particular focus on the role of mitochondrial metabolism.
2. In our biased approach we have established the involvement of the HIF-1 pathway in alveolar macrophage function and the importance of sensing oxygen for terminal differentiation (Izquierdo et al. Cell Reports. 2018). We are also analyzing other sensing pathways that affect DC and macrophage mitochondrial metabolism.
3. We have found a new function in inflammation of DCs (Del Fresno et al. Science. 2018) and a new pathway of sensing microbiota that affects immunity in the gut (Martínez-López et al. Immunity. 2019). This has potential impact as new functional targets that can be affected by the manipulation of mitochondrial metabolism, and we are currently exploring this avenue. In fact, we have recently described that Fgr kinase can modulate mitochondrial complex II activity and macrophage polarization, which affects host metabolism. Fgr promotes proinflammatory macrophage polarization, obesity and metabolic syndrome (Acín-Pérez et al. Nat Metab. 2020).
4. Our work has established that cDC1s can be effectively used for cancer immunotherapy (Wculek et al. JITC. 2019). The potential is to manipulate metabolism in cDC1s to improve cancer immunotherapy.
Título:
International Interdisciplinary PhD Studies in Biomedical Research - COFUND
Acrónimo
COFUNDImPRESS
Convocatoria:
H2020-MSCA-COFUND-2016
Referencia:
GA-754432
Investigador principal
Ana Dopazo
Fecha inicio:
01/02/2018
Fecha fin:
31/01/2023
Fuente de financiación:
EC-European Commission
Título:
Transgenerational epigenetic inheritance of cardiac regenerative capacity in the zebrafish
Acrónimo
TransReg
Convocatoria:
H2020-ERC-2018-CoG
Referencia:
GA-819717
Investigador principal
Nadia Mercader
Fecha inicio:
01/08/2019
Fecha fin:
31/01/2025
Presupuesto concedido:
326.250,00 €
Fuente de financiación:
EC-European Research Council
Título:
Novel mitochondria-targeting therapies for chemotherapy-induced cardiotoxicity
Acrónimo
Matrix
Convocatoria:
H2020-ERC-2018-CoG
Referencia:
GA-819775
Investigador principal
Borja Ibáñez Cabeza
Fecha inicio:
01/09/2019
Fecha fin:
31/05/2025
Presupuesto concedido:
1.473.437,50 €
Fuente de financiación:
EC-European Research Council
Título:
New-generation cardiac therapeutic strategies directed to the activation of endogenous regenerative
Acrónimo
REANIMA
Convocatoria:
H2020-SC1-BHC-07-2019
Referencia:
GA-874764
Investigador principal
Miguel Torres
Fecha inicio:
01/01/2020
Fecha fin:
30/06/2025
Presupuesto concedido:
1.380.000,00 €
Fuente de financiación:
EC-European Commission
Título:
Development of “smart” amplifiers of reactive oxygen species specific to aberrant polymorphonuclear neutrophils for treatment of inflammatory and autoimmune diseases, cancer and myeloablation.
Acrónimo
NeutroCure
Convocatoria:
H2020-FETOPEN-2018-2020
Referencia:
GA-861878
Investigador principal
Andrés Hidalgo Alonso
Fecha inicio:
01/01/2020
Fecha fin:
31/12/2024
Presupuesto concedido:
400.000,00 €
Fuente de financiación:
EC-European Commission
Título:
Personalized Prevention for Coronary Heart Disease
Acrónimo
CoroPrevention
Convocatoria:
H2020-SC1-BHC-25-2019
Referencia:
GA-848056
Investigador principal
Borja Ibáñez Cabeza
Fecha inicio:
01/01/2020
Fecha fin:
31/12/2026
Presupuesto concedido:
228.750,00 €
Fuente de financiación:
EC-European Commission
Título:
EXpansion and Phenotype Loss Of SMCs In Atherosclerosis: Causal effects and therapeutic possibilities
Acrónimo
EXPLOSIA
Convocatoria:
H2020-ERC-2019-COG
Referencia:
GA-866240
Investigador principal
Jacob Fog Bentzon
Fecha inicio:
01/08/2020
Fecha fin:
31/07/2025
Presupuesto concedido:
702.755,00 €
Fuente de financiación:
EC-European Research Council
Título:
European Research Training in Understanding the Molecular Regulation and the Role of EndoLysosomal Processes in Cardio-Metabolic Diseases
Acrónimo
EndoConnect
Convocatoria:
H2020-MSCA-ITN-2020
Referencia:
953489
Investigador principal
Miguel Ángel del Pozo Barriuso
Fecha inicio:
01/01/2021
Fecha fin:
31/12/2022
Fuente de financiación:
EC-European Commission
Título:
Machine learning artificial intelligence early detection stroke atrial fibrillation
Acrónimo
MAESTRIA
Convocatoria:
SC1-BHC-06-2020
Referencia:
GA-965286
Investigador principal
José Jalife Sacal
Fecha inicio:
01/03/2021
Fecha fin:
28/02/2026
Presupuesto concedido:
801.000,00 €
Fuente de financiación:
EC-European Commission
Título:
Understanding and modulating vascular arrest with ultra-high definition
Acrónimo
AngioUnrestUHD
Convocatoria:
H2020-ERC-2020-COG
Referencia:
GA-101001814
Investigador principal
Rui Benedito
Fecha inicio:
01/03/2021
Fecha fin:
28/02/2026
Presupuesto concedido:
1.998.500,00 €
Fuente de financiación:
EC-European Research Council
Título:
Rituximab in patients with acute myocardial infarction: a phase 2 placebo-controlled randomised clinical trial
Acrónimo
RITA ME 2
Convocatoria:
H2020-SC1-BHC-08-2020
Referencia:
GA-899991
Investigador principal
Borja Ibáñez Cabeza
Fecha inicio:
01/06/2021
Fecha fin:
31/05/2026
Presupuesto concedido:
53.957,50 €
Fuente de financiación:
EC-European Commission
Título:
Uncovering Protein Mechanics in Physiology and Disease
Acrónimo
ProtMechanics-Live
Convocatoria:
H2020-ERC-2020-COG
Referencia:
GA-101002927
Investigador principal
Jorge Alegre-Cebollada
Fecha inicio:
01/06/2021
Fecha fin:
31/05/2026
Presupuesto concedido:
2.000.000,00 €
Fuente de financiación:
EC-European Research Council
Título:
Remote Ischemic Conditioning in Lymphoma Patients Receiving Anthracyclines
Acrónimo
RESILIENCE
Convocatoria:
H2020-SC1-BHC-08-2020
Referencia:
GA-945118
Investigador principal
Borja Ibáñez Cabeza
Fecha inicio:
01/06/2021
Fecha fin:
31/05/2026
Presupuesto concedido:
1.725.938,00 €
Fuente de financiación:
EC-European Commission
Resumen:
RESILIENCE: a European Commission-funded project, coordinated by CNIC, aimed at reducing the incidence of heart failure in cancer survivors

Cancer survivors are at high risk for cardiovascular complications. Anthracyclines are an extremely effective treatment against many cancer types, but they can induce cardiac toxicity resulting in chronic heart failure. RESILIENCE will test a novel preventive intervention (remote ischemic conditioning) in patients at risk for anthracycline-induced cardiotoxicity. In addition, new diagnostic modalities will be used to identify anthracyclines-induced cardiotoxicity in its very early stages. RESILIENCE counts on a multidisciplinary consortium with the active participation of patients.
Título:
STING signalling modulation via the Electron Transport Chain
Acrónimo
STIMULATE
Convocatoria:
H2020-MSCA-IF-2019
Referencia:
GA-892965
Investigador principal
Gillian Dunphy
Fecha inicio:
01/07/2021
Fecha fin:
30/06/2023
Presupuesto concedido:
160.932,48 €
Fuente de financiación:
EC-European Commission
Título:
Functional relevance of mitochondrial supercomplex assembly in myeloid cells
Acrónimo
MY MITOCOMPLEX
Convocatoria:
H2020-MSCA-IF-2019
Referencia:
GA-893682
Investigador principal
Dieke Van Dinther
Fecha inicio:
01/11/2021
Fecha fin:
16/01/2024
Presupuesto concedido:
172.932,48 €
Fuente de financiación:
EC-European Commission
Título:
DecIphering nucLEar Mechanics in diabetes: a Multi-scAle perspective
Acrónimo
DILEMMA
Convocatoria:
HORIZON-MSCA-Postdoctoral Fellowships 2021
Referencia:
101065552
Investigador principal
Andra C. Dumitru
Fecha inicio:
01/06/2022
Fecha fin:
14/12/2022
Presupuesto concedido:
181.152,96 €
Fuente de financiación:
EC-European Commission
Título:
Enabling advances in diagnosis, patient stratification and treatment for dilated cardiomyopathy patients and families
Acrónimo
DCM-NEXT
Convocatoria:
HORIZON-EIC-2022-PATHFINDERCHALLENGES-01
Referencia:
101115416
Investigador principal
Enrique Lara Pezzi
Fecha inicio:
01/10/2023
Fecha fin:
30/09/2027
Presupuesto concedido:
461.000,00 €
Fuente de financiación:
EC-European Commission
Título:
Joint Action on CARdiovascular diseases and DIabetes
Acrónimo
JACARDI
Convocatoria:
EU4H-2022-PJ-11
Referencia:
101126953
Investigador principal
Héctor Bueno Zamora, Fátima Sánchez Cabo, Fátima Lois Díaz
Fecha inicio:
01/11/2023
Fecha fin:
31/10/2027
Presupuesto concedido:
1.093.154,00 €
Fuente de financiación:
EC-European Commission
Título:
Cure Heart and Brain
Acrónimo
Cure Heart and Brain
Convocatoria:
HORIZON-MSCA-COFUND-2022
Referencia:
GA-101126521
Investigador principal
Enrique Lara-Pezzi, María Ángeles Moro
Fecha inicio:
01/01/2024
Fecha fin:
31/12/2028
Presupuesto concedido:
1.719.360,00 €
Fuente de financiación:
EC-European Commission
Título:
Immunotherapy targeting marginal zone B lymphocytes to promote cardiac repair after acute myocardial infarction
Acrónimo
MARGINALIZE-MI
Convocatoria:
ERA4Health-CARDINNOV
Referencia:
ERA4HEALTHCVD-105
Investigador principal
Almudena Ramiro
Fecha inicio:
01/01/2024
Fecha fin:
31/12/2026
Fuente de financiación:
EC-European Commission
Título:
Human Antibody-enabled Cardiovascular Personalized Theranosis
Acrónimo
ABCardionostics
Convocatoria:
HORIZON-EIC-2023-PATHFINDEROPEN-01-01
Referencia:
101130308
Investigador principal
Carlos Perez Medina
Fecha inicio:
01/04/2024
Fecha fin:
31/03/2028
Presupuesto concedido:
503.065,00 €
Fuente de financiación:
EC-European Commission
Título:
Cardiac metabolic reprogramming by a nutritional intervention: High Fat diet for Heart Failure
Acrónimo
HF4HF
Convocatoria:
ERA4Health-CARDINNOV
Referencia:
ERA4HEALTHCVD-091
Investigador principal
Borja Ibáñez Cabeza
Fecha inicio:
01/05/2024
Fecha fin:
30/04/2027
Fuente de financiación:
EC-European Commission
Título:
A Blueprint of Inflammatory Drivers of Heart Failure with Preserved Ejection Fraction
Acrónimo
ID-PRESERVED
Convocatoria:
ERA4Health-CARDINNOV
Referencia:
ERA4HEALTHCVD-130
Investigador principal
Jose Javier Fuster
Fecha inicio:
01/05/2024
Fecha fin:
30/04/2027
Fuente de financiación:
EC-European Commission
Título:
Bridging the gap between cardiac and vascular regeneration
Acrónimo
RESCUE
Convocatoria:
ERA4Health-CARDINNOV
Investigador principal
Rui Benedito
Fecha inicio:
27/05/2024
Fecha fin:
26/05/2027
Fuente de financiación:
EC-European Commission
Título:
SK4 K+ channel blockers: a new anti-arrhythmic and anti-fibrotic treatment for atrial fibrillation
Acrónimo
SK4BLOCK-AFHF
Convocatoria:
ERA4Health-CARDINNOV
Referencia:
ERA4HEALTHCVD-087
Investigador principal
David Filgueiras Rama
Fecha inicio:
01/06/2024
Fecha fin:
31/05/2027
Fuente de financiación:
EC-European Commission
Título:
Targeting the Imidazole Propionate/Imidazoline I1 receptor axis as a novel treatment for Atherosclerosis
Acrónimo
ImnovAth
Convocatoria:
HORIZON-ERC-2023-PoC
Referencia:
GA-101158245
Investigador principal
David Sancho Madrid
Fecha inicio:
01/09/2024
Fecha fin:
28/02/2026
Presupuesto concedido:
150.000,00 €
Fuente de financiación:
EC-European Research Council
Título:
CONTRATO ENTRE LA FUNDACIÓN PARA EL CONOCIMIENTO MADRI+D Y CNIC PARA LA REALIZACIÓN DE ACTIVIDADES DEL PROYECTO LA NOCHE EUROPEA DE LOS INVESTIGADORES.
Acrónimo
NIGHT2024-2025
Convocatoria:
HORIZON-MSCA-2023-CITIZENS-01
Referencia:
CM-2024-036-09
Investigador principal
Irene Sánchez Nieto
Fecha inicio:
27/09/2024
Fecha fin:
26/09/2025
Presupuesto concedido:
2.500,00 €
Fuente de financiación:
EC-European Commission
Título:
The transcriptional regulation of cardiomyocyte polyploidization and its relevance in cardiac regeneration
Acrónimo
REACTIVA
Convocatoria:
HORIZON-ERC-2023-ADG
Referencia:
101142005
Investigador principal
Miguel Torres
Fecha inicio:
01/10/2024
Fecha fin:
30/09/2029
Presupuesto concedido:
2.500.000,00 €
Fuente de financiación:
EC-European Research Council
Título:
Computational biomechanics and bioengineering 3D printing to develop a personalized regenerative biological ventricular assist device to provide lasting functional support to damaged hearts
Acrónimo
BRAV3
Convocatoria:
H2020-SC1-BHC-07-2019
Referencia:
874827
Investigador principal
David Filgueiras Rama
Fecha inicio:
15/10/2024
Fecha fin:
30/06/2025
Presupuesto concedido:
100.000,00 €
Fuente de financiación:
EC-European Commission
Resumen:
Ischemic heart disease is the main cause of death in the EU, straining patients and economies. Regenerative Medicine has failed at delivering a definitive solution, and even the breakthrough of cell reprogramming, biomaterials or 3D printing, have not been able to find a curative solution. Generating a muscle with efficient pumping requires a careful recapitulation of the myocardial architecture. BRAV∃ is born with the ambition of shaping this quantum leap in the field. The overall concept is to provide a lasting functional support to injured hearts through the fabrication of regenerative personalized advanced tissue engineering-based biological ventricular assist devices (BioVADs). To do so, we will apply multimodal deep cardiac phenotyping, coupled to advanced Computational Modelling and biomechanical analysis in a large animal model of disease, to create a personalised 3D printable design. We will for the first time create a fibre-reinforced human heart-sized cardiac tissue able to recapitulate the low Young´s Modulus of the myocardium while withstanding pressures generated during the cardiac circle. Using the latest human induced pluripotent stem cell (hiPSC) technology and industrial-scale growth and differentiation, we will cellularize this novel human heart-sized constructs, creating a highly efficiently aligned cardiac tissue (including vasculature). BioVADs will be matured in in-Consortium built electromechanical stimulation bioreactors before transplantation in a porcine model of disease. We anticipate our BioVADs will constitute a one-shot regenerative treatment of IHD, decreasing the burden on healthcare providers and improving the quality of life of patients. Crucially, we will for the first time generate a wealth of information on heart development at a human scale. Delivering this novel application whilst developing the technological environment (bioreactor, chamber, pacemaker) will boost the capacity of the EU to grow economically and lead the field.